Multicentre, multinational randomised DBPC clinical trial for evaluation of safety and efficacy of specific immunotherapy with recombinant major allergens of Timothy grass pollen adsorbed onto aluminium-hydroxide in patients with IgE-mediated allergic rhinoconjunctivitis +/- controlled asthma.

Trial Profile

Multicentre, multinational randomised DBPC clinical trial for evaluation of safety and efficacy of specific immunotherapy with recombinant major allergens of Timothy grass pollen adsorbed onto aluminium-hydroxide in patients with IgE-mediated allergic rhinoconjunctivitis +/- controlled asthma.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2013

At a glance

  • Drugs Grass pollen allergy immunotherapy (Primary)
  • Indications Asthma; Grass pollen hypersensitivity; Rhinoconjunctivitis
  • Focus Registrational; Therapeutic Use
  • Acronyms AMETHYST
  • Most Recent Events

    • 08 Mar 2013 Planned end date changed from 1 Oct 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
    • 15 Mar 2012 Actual initiation date changed from Mar 2008 to Jan 2008 as reported by European Clinical Trials Database.
    • 15 Mar 2012 Planned number of patients changed from 498 to 750 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top